This site is intended for healthcare professionals

Moderna completes enrollment of phase III COVE study of mRNA vaccine against COVID-19 (mRNA-1273).

Read time: 1 mins
Last updated:28th Jun 2021
Published:22nd Oct 2020
Moderna, Inc., announced that it has completed enrollment of 30,000 participants for the Phase III COVE study of mRNA-1273 , its vaccine candidate against COVID-19, being conducted in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest